Erythrocyte membrane fluidity: A novel biomarker of residual cardiovascular risk in type 2 diabetes.
cardiovascular disease
cardiovascular risk assessment
fatty acids
fluorescence microscopy
machine-learning
membrane fluidity
type 2 diabetes
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
revised:
18
10
2023
received:
21
07
2023
accepted:
21
10
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
aheadofprint
Résumé
Improving the composition of circulating fatty acids (FA) leads to a reduction in cardiovascular diseases (CVD) in high-risk individuals. The membrane fluidity of red blood cells (RBC), which reflects circulating FA status, may be a valid biomarker of cardiovascular (CV) risk in type 2 diabetes (T2D). Red blood cell membrane fluidity, quantified as general polarization (GP), was assessed in 234 subjects with T2D, 86 with prior major CVD. Based on GP distribution, a cut-off of .445 was used to divide the study cohort into two groups: the first with higher GP, called GEL, and the second, defined as lower GP (LGP). Lipidomic analysis was performed to evaluate FA composition of RBC membranes. Although with comparable CV risk factors, the LGP group had a greater percentage of patients with major CVD than the GEL group (40% vs 24%, respectively, p < .05). Moreover, in a logistic regression analysis, a lower GP value was independently associated with the presence of macrovascular complications. Lipidomic analysis showed a clear shift of LGP membranes towards a pro-inflammatory condition due to higher content of arachidonic acid and increased omega 6/omega 3 index. Increased membrane fluidity is associated with a higher CV risk in subjects with T2D. If confirmed in prospective studies, membrane fluidity could be a new biomarker for residual CV risk assessment in T2D.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14121Subventions
Organisme : European Foundation for the Study of Diabetes
Organisme : Grant for "Innovative Measurements of Diabetes Outcomes 2018"
Organisme : Fondazione Associazione Medici Diabetologi
Organisme : Scholarship Adolfo Arcangeli to CMAC
Organisme : Italian Ministry of Education, University and Research
ID : GR-2018-12365577
Organisme : Italian Ministry of Education, University and Research
ID : RF-2019-12369293
Organisme : Università Cattolica del Sacro Cuore
ID : Fondi Ateneo Linea D.3.2, Fondi Ateneo Linea D.1, anno 2019 and Fondi Ateneo Linea D.1, anno 2020
Organisme : Italian Ministry of University and Research
ID : PRIN2020SH2ZZA
Informations de copyright
© 2023 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113.
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999-1008.
Stamler J, Vaccaro O, Neaton JD, Wentworth D, The Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-444.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941-950.
Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101(6):671-679.
Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.
Dziopa K, Asselbergs FW, Gratton J, Chaturvedi N, Schmidt AF. Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia. 2022;65(4):644-656.
Nelson AJ, Navar AM, Mulder H, et al. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the bypass angioplasty revascularization investigation 2 diabetes [BARI 2D] trial). Am J Cardiol. 2020;132:36-43.
Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40(2):537-557.
Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724-730.
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861.
ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540-1550.
Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281-1288.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.
Sherratt SCR, Juliano RA, Copland C, Bhatt DL, Libby P, Mason RP. EPA and DHA containing phospholipids have contrasting effects on membrane structure. J Lipid Res. 2021;62:100106.
Maulucci G, Cohen O, Daniel B, et al. Fatty acid-related modulations of membrane fluidity in cells: detection and implications. Free Radic Res. 2016;50(sup1):S40-S50.
Maulucci G, Cohen O, Daniel B, Ferreri C, Sasson S. The combination of whole cell lipidomics analysis and single cell confocal imaging of fluidity and micropolarity provides insight into stress-induced lipid turnover in subcellular organelles of pancreatic beta cells. Molecules. 2019;24(20):3742.
Ciasca G, Papi M, di Claudio S, et al. Mapping viscoelastic properties of healthy and pathological red blood cells at the nanoscale level. Nanoscale. 2015;7(40):17030-17037.
Bianchetti G, di Giacinto F, Pitocco D, et al. Red blood cells membrane micropolarity as a novel diagnostic indicator of type 1 and type 2 diabetes. Anal Chim Acta X. 2019;3:100030.
Maulucci G, Cordelli E, Rizzi A, et al. Phase separation of the plasma membrane in human red blood cells as a potential tool for diagnosis and progression monitoring of type 1 diabetes mellitus. PloS One. 2017;12(9):e0184109.
van der Vegt SG, Ruben AM, Werre JM, et al. Counterflow centrifugation of red cell populations: a cell age related separation technique. Br J Haematol. 1985;61(3):393-403.
Breil C, Abert Vian M, Zemb T, Kunz W, Chemat F. “Bligh and Dyer” and Folch methods for solid-liquid-liquid extraction of lipids from microorganisms. Comprehension of solvatation mechanisms and towards substitution with alternative solvents. Int J Mol Sci. 2017;18(4):708.
Murtagh F, Contreras P. Algorithms for hierarchical clustering: an overview. Wiley Interdiscip Rev Data Min Knowl Discov. 2012;2:86-97.
Fruchart JC, Sacks F, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10 Suppl):1K-34K.
Field CJ, Ryan EA, Thomson AB, Clandinin MT. Diet fat composition alters membrane phospholipid composition, insulin binding, and glucose metabolism in adipocytes from control and diabetic animals. J Biol Chem. 1990;265(19):11143-11150.
Pakiet A, Jakubiak A, Mierzejewska P, et al. The effect of a high-fat diet on the fatty acid composition in the hearts of mice. Nutrients. 2020;12(3):824.
Sonnweber T, Pizzini A, Nairz M, Weiss G, Tancevski I. Arachidonic acid metabolites in cardiovascular and metabolic diseases. Int J Mol Sci. 2018;19(11):3285.
Tanaka N, Irino Y, Shinohara M, et al. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J. 2018;82(2):596-601.
Artiach G, Carracedo M, Plunde O, et al. Omega-3 polyunsaturated fatty acids decrease aortic valve disease through the Resolvin E1 and ChemR23 Axis. Circulation. 2020;142(8):776-789.
Yamada N, Takita T, Wada M, Kannke Y, Innami S. Effects of dietary n-3/n-6 and polyunsaturated fatty acid/saturated fatty acid ratios on platelet aggregation and lipid metabolism in rats. J Nutr Sci Vitaminol (Tokyo). 1996;42(5):423-434.
Kashiyama T, Ueda Y, Nemoto T, et al. Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio. Circ J. 2011;75(10):2432-2438.
Zhang Y, Sun Y, Yu Q, et al. Higher Ratio of Plasma Omega-6/Omega-3 Fatty Acids Is Associated with Greater Risk of all-Cause, Cancer, and Cardiovascular Mortality: a Population-Based Cohort Study in UK Biobank. medRxiv. 2023. doi:10.1101/2023.01.16.23284631.
Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34.
Das UN. Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: a review. J Adv Res. 2018;11:43-55.
Takkunen MJ, De Mello VDF, Schwab US, Ågren JJ, Kuusisto J, Uusitupa MIJ. Associations of erythrocyte membrane fatty acids with the concentrations of C-reactive protein, interleukin 1 receptor antagonist and adiponectin in 1373 men. Prostaglandins Leukot Essent Fatty Acids. 2014;91(4):169-174.
Fontes JD, Rahman F, Lacey S, et al. Red blood cell fatty acids and biomarkers of inflammation: a cross-sectional study in a community-based cohort. Atherosclerosis. 2015;240(2):431-436.
de Lorgeril M, Renaud S, Salen P, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343(8911):1454-1459.